3,177 reports of this reaction
3.4% of all GEMCITABINE HYDROCHLORIDE reports
#4 most reported adverse reaction
NEUTROPENIA is the #4 most commonly reported adverse reaction for GEMCITABINE HYDROCHLORIDE, manufactured by Armas Pharmaceuticals Inc.. There are 3,177 FDA adverse event reports linking GEMCITABINE HYDROCHLORIDE to NEUTROPENIA. This represents approximately 3.4% of all 92,220 adverse event reports for this drug.
Patients taking GEMCITABINE HYDROCHLORIDE who experience neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUTROPENIA is moderately reported among GEMCITABINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to neutropenia, the following adverse reactions have been reported for GEMCITABINE HYDROCHLORIDE:
The following drugs have also been linked to neutropenia in FDA adverse event reports:
NEUTROPENIA has been reported as an adverse event in 3,177 FDA reports for GEMCITABINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUTROPENIA accounts for approximately 3.4% of all adverse event reports for GEMCITABINE HYDROCHLORIDE, making it a notable side effect.
If you experience neutropenia while taking GEMCITABINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.